Clinical and laboratory work-up prior to hormone replacement therapy in postmenopausal women.
In a retrospective study on 100 female patients (mean age 52 years), with a menopause lasting for 3.5 years, referred to the Menopausal Clinic of Beilinson Medical Center, we studied the pretreatment, clinical and laboratory work-up before administration of hormone replacement therapy (HRT). The work-up consisted of clinical and medical examination and history. Mammography is a necessary test for malignancy exclusion, and also the assessment of lipid metabolism. Pap smear is not so important since cervical cancer is a rare event in Jewish women and pelvic sonography cannot be a decisive diagnostic tool for ruling out malignancy. We conclude that HRT for prevention of osteoporosis and cardiovascular disease should be administered in a menopausal clinic by a gynecologist, after performing a few tests: confirmation of menopause by follicle-stimulation hormone (FSH) and E2, excluding malignancy by mammography, and confirmation of normal lipid metabolism.
Pardo
J
J
Department of Obstetrics and Gynecology, Beilinson Medical Center, Petah-Tiqva, Israel.
Kaplan
B
B
Neri
A
A
Blum
M
M
D002985:Clinical Protocols; D003955:Diagnostic Tests, Routine; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy / Q000592:standards*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008327:Mammography; D008593:Menopause / Q000097:blood; D008875:Middle Aged; D065006:Papanicolaou Test; D010808:Physical Examination; D012189:Retrospective Studies; D014626:Vaginal Smears
D008055:Lipids; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone